Or at least that's what the president of Comcast Advertising, James Rooke, said during an interview on Wednesday at CES 2025 ...

The newly launched biotech is equipped with rights to a trio of weight loss medicines licensed from China-based Sciwind ...

AI hardware company specializing in smart office solutions, made a stunning debut at CES 2025 debut from January 7-10.

French startup Rounded believes AI voice agents are going to become the default way customers interact with companies, so ...

Vertex Pharmaceuticals and Orna Therapeutics announce a $4 billion collaboration to develop in vivo gene editing therapies ...

Orna will receive a $65m upfront payment and is eligible to receive potential milestone payments and royalties.

About four years after launch, Orna Therapeutics Inc. signed its second major deal, this time validating the lipid nanoparticle delivery technology it acquired through its Renagade Therapeutics Inc.

The three-year partnership is another example of Vertex’s interest in improving on Casgevy, its CRISPR medicine for sickle ...

Vertex Pharmaceuticals Inc. will work with a Watertown biotech on new gene-editing therapies for people with sickle cell ...

The deal is set to help Vertex’s development of next-generation gene editing therapies for sickle cell disease and ...

Vertex aims to further bolster its gene-editing therapy pipeline by using Orna's lipid nanoparticle delivery technologies during the three-year collaboration.

Vertex partners with Orna Therapeutics to develop in vivo gene editing treatments for sickle cell disease and beta ...